23andme CEO Anne Wojcicki moves to take company private

After a tumultuous experience on the public markets, 23andMe CEO Anne Wojcicki is moving to take the company private.

Wojcicki disclosed her plans in a filing with the Securities and Exchange Commission late Wednesday, saying that she intends to seek out potential partners and financiers to help. Wojcicki currently holds 49.99% of the voting power in the company, according to the Wall Street Journal, which first reported on the plan.

The company was once an industry darling, its star rising — and then falling — with the consumer genetics boom of the 2010s. For many years, the company’s main business has been selling at-home testing genetic kits, but Wojcicki has pushed the company to use the genetic insights gleaned from millions of consumer samples to create new medicines.

Get unlimited access to award-winning journalism and exclusive events.

Teva fined €462.6M by European regulators over Copaxone patent and competition allegations

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 1, 2024

CMS Drops Controversial Proposal for Blood Tests After Organ Transplant

The Centers for Medicare & Medicaid Services (CMS) dropped a proposed policy to further delineate Medicare coverage for the types of blood tests that organ

August 23, 2024

Ascend Wellness Q2 Revenue Increases to Record $123 Million

AWH ANNOUNCES Q2 2023 FINANCIAL RESULTS Reported Record Quarterly Revenue Achieved $123.0M Net Revenue in Q2 2023, a 26.1% Increase Year-Over-Year and 7.7% Increase Quarter-Over-Quarter

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.